Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
Kobayashi
K
K
Vokes
E E
EE
Vogelzang
N J
NJ
Janisch
L
L
Soliven
B
B
Ratain
M J
MJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D013498:Suramin / Q000008:administration & dosage* / Q000009:adverse effects
D000970:Antineoplastic Agents; D013498:Suramin